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Patient and graft outcomes from older living kidney donors are
similar to those from younger donors despite lower GFR.
Background. Donor age adversely affects deceased-donor
kidney transplant outcomes, but its influence on living-donor
transplantation is less well characterized.
Methods. Living-donor kidney transplants at a single center
between 1998 and 2000 were reviewed. Data were abstracted for
52 transplants from donors aged ≥50 years and for a matched
group of 104 transplants from donors aged <50 years. Sur-
vival indices were compared during the first three years’ post-
transplantation. Functional indices, including serial iothalamate
clearances, were compared at 1, 12, and 24 months.
Results. Predonation glomerular filtration rate (GFR) was
lower among older donors (94 ± 12 vs. 108 ± 17 mL/min/SA) but
post-transplant compensatory hypertrophy was similar (11.7 ±
26.3% vs. 7.7 ± 31.4%). Recipients of older-donor grafts were
older (52.8 ± 16.5 vs. 46.1 ± 15.1 years) and more frequently
unrelated to the donor (54% vs. 39%). Trends toward higher
frequency of slow graft function, cytomegalovirus (CMV) infec-
tion, and polyomavirus nephropathy were observed for older-
donor grafts. Three-year recipient, graft, and death-censored
graft survivals were ≥90% for both groups. At 1, 12, and
24 months, serum creatinine was higher and GFR was lower
among recipients of older- compared with younger-donor grafts.
Other functional indices (urine total protein, serum potassium
and uric acid, hemoglobin, and number of antihypertensives)
were not different. Donor age correlated with graft GFR at
1, 12, and 24 months for the entire study cohort by linear
regression.
Conclusion. Older donor age does not preclude excellent re-
sults from living-donor kidney transplantation but should be
appreciated as being associated with relatively lower GFR.
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Advanced donor age exerts a profound adverse influ-
ence on outcomes for deceased donor kidney transplants
[1]. In most, but not all, large studies of kidney transplant
outcome, donor age greater than 50 years is identified as
a strong independent predictor of poorer graft survival
[1–10]. The clinical impact of the “donor age effect” has
increased in recent years as utilization of kidneys from ex-
tended criteria deceased donors has grown in an attempt
to address organ shortage [11]. The pathophysiologic
mechanisms by which older kidneys lose function after
transplantation are incompletely understood, but may
involve both early and late-onset processes [2, 12–15].
Concerns regarding the effects of older donor age on re-
nal transplant success have also influenced living donor
acceptance practice at many centers. It is not uncommon
for older individuals to be discouraged from donation in
favor of a younger living donor or of placement on the
waiting list for a deceased donor organ. Whether donor
age exerts a similar negative influence on the outcome
of living donor kidney transplantation is poorly under-
stood. Living donor transplantation allows avoidance of
donors with significant cardiovascular disease or border-
line renal function, as well as minimization of ischemia-
reperfusion injury. Existing literature on outcomes for
living donor kidney transplants from older donors (most
commonly designated as donor age of 50 years or greater)
includes reports of equivalent graft survival, as well as
of reduced graft survival compared to transplants from
younger donors [16–27]. In addition, while the donor age
effect has continued to be apparent for deceased donor
grafts in the current “post cyclosporine” era of immuno-
suppression [2], it is possible that recent reduction in
early acute rejection rates represents an advantage for
living donor transplants from older donors. Finally, al-
though glomerular filtration rate (GFR) declines with
age, few studies of living donor kidney transplants include
accurate longitudinal GFR measurements by which
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trends in actual graft function can be examined for dif-
ferent donor subgroups [24].
Our center has emphasized the advantages of living
donor transplantation for the recipient, as well as the
requirement to fully educate potential donors regarding
the outcomes for both of the individuals involved [28]. In
this report we compare multiple indices of renal allograft
success, including accurately measured GFR, in recently
transplanted recipients of living donor transplants from
donors aged greater than or less than 50 years. The re-
sults demonstrate similar patient and graft survival for
older living donor graft recipients compared to grafts
from younger donors, but also highlight the fact that these
transplants represent a subgroup with lower initial and
subsequent GFR.
METHODS
Study subjects
A total of 412 adult and pediatric kidney transplants
were performed at Mayo Clinic, Rochester, Minnesota,
from January 1, 1998 to October 31, 2000, 252 of which
were from living-related or living-unrelated donors. Ten
living donor transplants involving specialized protocols
for ABO incompatible or positive cytotoxicity cross-
match donors were excluded from consideration, leaving
a pool of 242 cases. Of these, 52 (22%) transplants were
from donors aged 50 years or more. This group was des-
ignated the “older donor group.” For each older donor
transplant, records of two transplants from living donors
aged <50 years old were reviewed. Each pair of younger
donor transplants was matched with its older donor coun-
terpart for donor gender and month of transplantation.
This group of 103 transplants from living donors aged
less than 50 years was designated the “younger donor”
group. Clinical records of each donor and recipient were
reviewed, and demographic, clinical, and laboratory data
were abstracted. Donor characteristics, graft and patient
survival, GFR measurements by iothalamate clearance,
hematologic, and biochemical indices were recorded. For
the purpose of this study, patients who received more than
one renal allograft in the study time frame were consid-
ered only once, and censored when they lost the allograft.
For transplant recipients, the study end point was death,
graft loss, or last recorded status up to October 31, 2002.
Donor acceptance criteria
Blood group compatible potential living kidney donors
undergo medical, surgical, social, and educational con-
sultations; hematology and chemistry panels; fasting
blood glucose measurement; chest x-ray; electrocardiog-
raphy; tissue typing; infection screening; age- and gender-
appropriate cancer screening; urinalysis; urine protein
quantification; measurement of GFR by iothalamate
clearance; and assessment of renal anatomy by CT
angiography with excretory urography. Following this
evaluation, criteria for final acceptance include voluntary
informed consent with no indication of coercion; lack of a
medical or surgical contraindication to donation; and ac-
ceptable renal anatomy and function. Acceptable renal
function is defined as GFR greater than the 5% percentile
for normal individuals of the same gender and age to an
absolute lower acceptable limit of 70 mL/min for older
potential donors [18, 29].
Definitions
Acute rejection (AR) was defined as biopsy-diagnosed
acute cellular rejection (Banff grade IA or greater)
treated with intravenous methylprednisolone or T-cell–
depleting antibody. Slow graft function (SGF) was
defined as failure of immediate preoperative serum crea-
tinine concentration to halve within the first 72 hours’
post-transplant. GFR was measured by iothalamate
clearance corrected for calculated body surface area and
expressed as mL/min/1.73m2 [18]. Donor prenephrec-
tomy GFR was measured during the donor evaluation.
Recipient GFR was measured at the time of initial out-
patient clinic dismissal (generally 3 to 4 weeks’ post-
transplant) and at 4, 12, and 24 months’ post-transplant.
CMV infection was defined as a systemic febrile illness or
organ-specific syndrome with one or more of the follow-
ing: (1) positive blood polymerase chain reaction (PCR)
test for CMV DNA; (2) culture of CMV from blood or
tissue-biopsy; (3) characteristic viral inclusions on a tis-
sue biopsy. Polyomavirus (BK)-associated nephropathy
(PVAN) was defined as characteristic histologic abnor-
malities on a renal transplant biopsy (intranuclear viral
inclusions in tubular epithelial cells and tubulointerstitial
cellular infiltrates) with positive in situ hybridization for
BK viral DNA in multiple tubular epithelial cell nuclei.
Compensatory increase in filtration (CIF) was defined
as the proportionate increase in baseline GFR that oc-
curred in the transplanted kidney within the first 3 to
4 weeks’ post-transplantation [30]. For this purpose it
was assumed that the donor prenephrectomy GFR rep-
resented equal contributions from left and right kidneys
(i.e., the transplanted kidney’s baseline GFR was 50%
of the donor prenephrectomy GFR). The formula to cal-
culate CIF was: CIF = 100 (recipient GFR at 1 month
−50% of donor prenephrectomy GFR)/50% of donor
prenephrectomy GFR).
Statistical analysis
Patient, graft, and death-censored graft survivals were
analyzed by Kaplan-Meier estimator for survival dis-
tribution and compared using the log-rank test. For
comparison of clinical and laboratory data between
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Table 1. Donor baseline characteristics
Group 1 Group 2
(Age ≥50 years) (Age <50 years) P
Characteristic (N = 52) (N = 103) value
Age in years 56.3 ± 6.1/50–71 36.6 ± 8.7/17–49 <0.0001
(mean ± SD/range)
Gender 22/30 49/54 0.53
(M/F)
Race % 0.68
Caucasian 92 89
African 2 2
American
Hispanic 4 2
Asian/Pacific 0 3
Islander
Serum creatinine 1.03 ± 0.17 1.05 ± 0.17 0.61
mg/dL (mean ± SD)
Iothalamate clearance 94.0 ± 12.4 108.0 ± 17.3 <0.0001
mL/min/SA
(mean ± SD) (range 70–127) (range 74–155)
donor and recipient groups, unpaired t test, Wilcoxon
nonparametric test, chi-square test, and Fisher analysis
was used as appropriate. Donor age was correlated as a
continuous variable with recipient GFR by linear regres-
sion analysis. P values < 0.05 were considered statistically
significant.
RESULTS
Characteristics of donor and recipients groups
Fifty-two renal transplants involving living donors aged
50 years or more, and 103 transplant involving living
donors aged less than 50 years were included in the study.
All transplants were carried out between 1998 and 2000.
Older and younger donor cases were matched for donor
gender and month of transplantation. Table 1 summa-
rizes baseline characteristics of the donors in the two
groups. The mean age of the older donor group was 56.3 ±
6.1 years (range 50 to 71 years) compared to 36.6 ± 6.1
years (range 17 to 49 years) for the younger donors. The
donors were predominantly Caucasian in both groups.
Although serum creatinine concentration did not differ
between the two donor groups at the time of donor eval-
uation, the mean GFR, measured by iothalamate clear-
ance, was lower for the older donors (94 ± 12 vs. 108 ±
17 mL/min/1.73 m2, P <.01). Characteristics of the trans-
plant recipients for the two groups are shown in Table 2.
Recipients of older living donor transplants were older
(52.8 ± 16.5 vs. 46.1 ± 15.1 years, P = 0.01) and more
likely to receive a kidney from an unrelated donor (54%
vs. 39%, P = 0.04). The two recipient groups did not
differ regarding gender, ethnicity, frequency of diabetes
mellitus, weight at transplantation, cause of renal failure,
frequency of retransplantation or of preemptive trans-
plantation, CMV serologic status, use of induction ther-
apy, or immunosuppressive regimen employed.
Table 2. Recipient baseline characteristics
Group 1 Group 2
(Donor ≥50 (Donor <50
years) years) P
Characteristic (N = 52) (N = 103) value
Age in years 52.8 ± 16.5/19–81 46.1 ± 15.1/12–73 0.013
(mean ± SD/Range)
Gender (M/F) 28/24 66/37 0.22
Diabetes % 27 37 0.21
Race % 0.46
Caucasian 94 93
African American 2 1
Hispanic 2 3
Native American 2 0
Asian/Pacific 0 3
Islander
Weight kg 80.4 ± 18.0 80.4 ± 20.6 0.99
(mean ± SD)
Primary renal disease % 0.67
Diabetes mellitus 25 32
Hypertension 6 3
Glomerulonephritis 37 28
Congenital/hereditary 4 5
Other 29 32
Retransplant % 13 20 0.28
Preemptive transplant % 39 40 0.87
CMV serologic status % 0.87
Donor positive/ 39 43
recipient positive
Donor positive/ 21 17
recipient negative
Donor negative/ 19 21
recipient negative
Donor negative/ 21 19
recipient positive
HLA match % 0.04
Related–two 4 7
haplotype
Related–one 35 47
haplotype
Related–zero 8 17
haplotype
Unrelated 54 39
Antibody induction % 39 30 0.55
Immunosuppressive 0.77
regimen %
CSA + MMF + PRED 23 28
TAC + MMF + PRED 67 64
Other 10 8
Abbreviations are TAC, tacrolimus; CSA, cyclosporine; MMF, mycophenolate
mofetil; PRED, prednisone; other regimens, TAC + Sirolimus (SRL) + PRED;
SRL + MMF + PRED; CYA + SRL + PRED.
Compensatory hypertrophy and acute transplant
complications
By using donor prenephrectomy GFR measurements
and recipient GFR measured at the time of initial out-
patient clinic dismissal (generally 3 to 4 weeks’ post-
transplant) it was possible to calculate the proportionate
compensatory increase in GFR that occurred for both
older and younger living donor grafts. As shown in
Table 3, CIF for grafts from donors aged 50 or more years
was not different from that which occurred for younger
donor grafts. The frequency of slow initial graft function
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Table 3. Clinical events among the two recipient groups during the
first year post-transplant
Group 1 Group 2
(Age ≥ 50 yrs.) (Age <50 yrs.) P
Clinical outcomea (N = 52) (N = 103) value
Compensatory increase 11.7 ± 26.3% 7.7 ± 31.4% NS
in filtration (mean ± SD)
Slow graft function % 19 10 NS
Acute rejection % 32 29 NS
CMV disease % 10 5 NS
Polyomavirus-associated 8 2 NS
nephropathy %
aSee Methods for definitions.
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Fig. 1. Recipients of older and younger living donor kidney transplants
have similar graft and patient survival to three years’ post-transplant.
Kaplan Meier survival curves between 0 to 36 months’ post-transplant
are shown for overall graft survival (upper), patient survival (lower left),
and death-censored graft survival (lower right) of patients receiving
living donor kidney transplant from donors aged less than 50 years
(dashed lines) or donors aged 50 years or greater (solid lines). For all
three survival indices, no significant differences are present between the
two groups.
was higher for older donor grafts (19% vs. 10%), but the
difference was not statistically significant. Likewise, there
were nonsignificant trends during the follow-up period
toward increased frequencies of acute rejection (clinical
or subclinical, 32% vs. 29%), CMV disease (10% vs. 5%),
and development of PVAN (8% vs. 2%) among recipients
of older donor transplants (Table 3).
Graft survival and function
Overall graft survival, patient survival, and death-
censored graft survival up to three years’ post-transplant
(median follow-up 31 months and 29 months for recip-
ients of older and younger donor grafts, respectively)
were ≥90% among recipients of living donor grafts from
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Fig. 2. Recipients of older living donor kidney transplants have higher
average serum creatinine concentration and lower average glomerular
filtration rate (GFR) compared to recipients of younger living donor
kidney transplants. Serum creatinine concentrations (A) and iothala-
mate clearances (B) are shown for recipients of living donor kidney
transplants from donors aged less than 50 years (gray circles) or donors
aged 50 years or greater (black circles). Results at 1, 12, and 24 months
post-transplantation are expressed as mean ± SD, and the number of
patients for which results were available at each time point is indicated.
†P < 0.05 for older donor recipients vs. younger donor recipients.
both older and younger donors. (Fig. 1). Nonetheless,
graft function, as measured by serum creatinine concen-
tration as well as by iothalamate clearance at 1, 12, and
24 months’ post-transplant, was lower among older donor
recipients (Fig. 2). At 1 month post-transplant, GFR mea-
surements for 46 older donor and 77 younger donor trans-
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Fig. 3. Recipient glomerular filtration rate (GFR) is inversely corre-
lated with living donor age at 1, 12, and 24 months post-transplant. The
relationship between living donor age and recipient GFR (iothalamate
clearance corrected for body surface area) is shown as linear regression
plots of available results for the entire study population at 1, 12, and
24 months post-transplant. At each time point following transplanta-
tion a significant inverse correlation between donor age and GFR was
evident.
plants were 51.6 ± 17.8 and 56.3 ± 15.7, respectively. At
2 years’ post-transplant, GFR measurements were avail-
able for 30 recipients of older donor transplants and for
48 recipients of younger donor grafts and were 47.0 ± 19.1
and 55.0 ± 18.2, respectively. The trend toward decline in
GFR between 1 month and 2 years for older donor grafts
was not significant, even when only those transplants with
GFR measurements at both time points were subjected
to paired analysis (P = 0.26).
When the correlation between donor age and recipient
GFR was evaluated for the entire study cohort by linear
regression analysis, a clear inverse relationship could be
demonstrated (Fig. 3). This correlation was present at
1 month, 12 months, and 24 months’ post-transplant and
was, in fact, strengthened rather than weakened at the
later time points (r2 = 0.05 at 1 month, 0.12 at 12 months,
and 0.15 at 24 months).
Additional laboratory and clinical post-transplant indices
Median 24-hour urine protein excretion was closely
comparable between the two groups of recipients at one
year (older donor grafts 0.20 g/24 hr, younger donor grafts
0.22 g/24 hr; P = 0.39) and at two years’ (older donor
grafts 0.10 g/24 hr, younger donor grafts 0.19 g/24 hr; P =
0.56) post-transplantation. Similarly, there were no dif-
ferences or notable trends toward differences between
older and younger donor grafts for serum potassium, uric
acid, hemoglobin, and number of antihypertensive med-
ications (data not shown). In addition, neither group of
recipients demonstrated trends toward a change in any of
these indices between the first and second post-transplant
year.
DISCUSSION
Our results indicate that living kidney donors above
age 50 have lower GFRs before nephrectomy, and that
their recipients have lower GFR at each time point from
1 month to 2 years’ post-transplantation. Despite this,
recipient and graft survival did not differ between the
two groups during a median follow-up of 30 months af-
ter transplantation, nor did recipient urine protein ex-
cretion and severity of hypertension differ during the
first two years. These data suggest that satisfactory clin-
ical outcomes from older living donors can be achieved
compared with those from younger donors. In comparing
these results with those for deceased donor renal trans-
plants, it is important to emphasize that both older and
younger living donors represent carefully screened indi-
viduals with excellent overall health and high motivation
to donate. In addition, the opportunity to accurately mea-
sure GFR prior to donation, rather than rely on formula-
based GFR calculation, allows for the exclusion of indi-
viduals with renal function below accepted age-specific
normal levels.
The benefits of receiving a kidney transplant from a
living donor include the opportunity to avoid or mini-
mize time on dialysis and the overall superior outcomes
for living donor compared to deceased donor grafts irre-
spective of HLA matching [28, 31]. Living donors can also
be viewed as making a valuable societal contribution by
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potentially reducing the rate of growth of the waiting list
for deceased donor organs. For the medical team coordi-
nating living donor kidney transplantation it is essential
to be able to provide as accurate an assessment of the risks
and benefits involved for a given donor-recipient pair as
possible. This responsibility has become more complex
in recent years with trends toward an overall increase
in living donation, and toward the cautious acceptance
of living donors that would previously have been con-
sidered unsuitable or of borderline suitability [32]. Our
study, which compares graft outcomes from recent older
and younger living donor transplants, indicates that the
early detrimental effect of older donor age seen with de-
ceased donor grafts is essentially abolished when care-
fully selected living donors are involved. In this respect,
the results represent a confirmation of the experiences
reported by a limited number of centers for living donor
transplants carried out over several decades [17, 20, 23,
24].
The influence of predonation GFR on renal transplant
outcome was directly demonstrated by Norde´n et al [22]
in a cohort of 344 living-donor grafts at a Swedish center.
In this report, graft survival during five years of follow-
up was reduced when the uncorrected GFR of the donor
was <80 mL/min. The authors reasoned that “any im-
pact of donor age on graft is linked to a lower donor
GFR.” Our study also emphasizes the importance of
donor prenephrectomy GFR as a determinant of the post-
transplant function of living donor grafts. By examining
serial accurate measurements of GFR, we show that kid-
ney grafts from living donors aged 50 years or more can be
expected to have a lower level of actual function during
the early post-transplant years. We also show that a con-
tinuous relationship exists between living donor age and
recipient GFR up to two years’ post-transplantation. Our
results cannot, therefore, exclude the possibility that re-
cipients of older living donor grafts may be more vulnera-
ble to late renal insufficiency or failure. This possibility is
supported by the findings of Toma et al [20], who, in a se-
ries including 343 allografts from Japanese living donors
aged 60 years or more, observed significantly poorer sur-
vival of the older donor grafts beginning only at five years’
post-transplant [20]. Similarly, Matas et al [19] have re-
cently reported that donor age greater than 55 years is a
significant risk factor for late graft loss in an analysis of the
entire living donor kidney transplant experience (2500 al-
lografts) at the University of Minnesota. This late effect of
donor age has also been highlighted for deceased donor
grafts in some studies. For example, Prommool et al [13]
found that, once the association with delayed graft func-
tion was controlled for, the negative influence of donor
age ≥55 years on graft survival occurred predominantly
at five or more years post-transplantation. Interestingly,
we did not find a deficit in compensatory hypertrophy
in older compared to younger donor kidneys. Thus, al-
though possessing a lower GFR on average, the older
kidney need not necessarily be viewed as having less func-
tional reserve—a circumstance that would imply high risk
of hyperfiltration injury [33]. In keeping with this, urine
protein excretion at one and two years post-transplant
was no different for the two groups of recipients. Hal-
loran has pointed out the similarities between some of
the histologic features of chronic allograft nephropathy
and those of the aging kidney, and has proposed a role
for cellular senescence in the decline of renal transplant
function over time [12, 34]. By this conceptual frame-
work, the older transplanted kidney may be more prone
to gradual loss of function over time through the ongoing
deterioration of tissue repair mechanisms. An important,
and testable, hypothesis related to this model is that the
older living donor graft may be more vulnerable to cal-
cineurin inhibitor toxicity or other nephrotoxic insults.
Further understanding of the pathophysiology underly-
ing lower GFR among older living kidney donors may
be garnered from careful histologic and molecular anal-
ysis of serial protocol surveillance biopsies from living
donor grafts [35, 36]. Although the degree of glomeru-
losclerosis is commonly used to estimate the failure risk
associated with a given deceased donor kidney, quantita-
tive or semiquantitative measurement of baseline vascu-
lar and tubulointerstitial abnormalities may prove to be
more predictive of subsequent loss of function of living
donor grafts.
The observation that GFR is lower during the first two
years’ post-transplant for recipients of living donor renal
allografts from donors aged 50 years or more underscores
the opportunity that exists to design early interventional
protocols that may serve to better preserve function for
this subgroup of recipients. In contrast to deceased donor
transplantation, where events occurring before or during
organ harvest may profoundly limit the functional po-
tential of an older kidney, the relative stability of the
living donor graft during the initial years should pro-
vide a window for introducing renoprotective therapies.
Among the therapeutic maneuvers that could be envis-
aged as having special potential for recipients of older
living donor grafts are late minimization or withdrawal
of calcineurin inhibitor therapy, do novo or early intro-
duction of sirolimus-based immunosuppressive regimens
[37], or aggressive use of renin-angiotensin system block-
ade. Although there were no statistically significant dif-
ferences between our two study groups for specific ad-
verse outcomes it is noteworthy that there were trends
toward higher frequency of slow graft function, CMV dis-
ease, and PVAN. Because the recipients of older donor
transplants were older and less well matched for HLA
genotype, it is certainly possible that these trends partly
or entirely reflect recipient-related effects. Nonetheless,
our experience raises the possibility that these sources
of morbidity may be more common in the context of
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transplantation involving an older living donor, and may
also represent areas for which modified therapeutic pro-
tocols or enhanced surveillance strategies could improve
overall outcomes.
CONCLUSION
The results of our study and the small number of stud-
ies like it may be considered, first and foremost, as be-
ing supportive of the acceptance of older living donors
who are highly motivated to donate, and who meet care-
fully constructed medical criteria. Even in the context
of a probable long-term difference in graft survival be-
tween younger and older living donor grafts, the cir-
cumstances in which waiting for a deceased donor kid-
ney is truly preferable to living donor transplantation
are both rare and unpredictable [38]. The observation
that a greater proportion of the older living donor trans-
plants at our center involved nongenetically related re-
cipients primarily reflects the relatively common situa-
tion of spousal donation—a decision that many couples
view as the their logical best choice. The excellent early
outcomes for older donor living transplantation also le-
gitimize offering this choice to potential recipient/donor
couples of advanced age for whom the lengthy wait for
a deceased donor graft would be highly undesirable. In-
deed, the “old for old” matching that has met with varying
enthusiasm in the realm of deceased donor transplanta-
tion [39] may be far better suited conceptually to living
donation.
Our study does not address the risk to the older kid-
ney donor of perioperative adverse events or of fu-
ture loss of renal function, although, clearly, these is-
sues are of equal importance in evaluating and educat-
ing each potential donor/recipient pair [40]. Long-term
analysis of donor outcomes at our center, at other cen-
ters for which living donor transplantation represents
a growing practice, and at the level of national regu-
latory bodies has recently taken on even higher prior-
ity, and undoubtedly will be required to ensure that the
overall benefits of this procedure continue to justify its
expansion.
Reprint requests to Matthew D. Griffin M.B., BCh, Mayo Clinic and
Foundation, 200 First St. SW, Charlton 10 Transplant Center, Rochester,
MN 55905.
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